About Dr. Harvey A. Fishman
- M.D. Stanford University Medical School 2000
- Ph.D. Stanford University
- Analytical Chemistry with a Neuroscience emphasis 1995
- B.S. Penn State University Chemistry 1990
- Board-Certified Physician, California
- United States Medical Licensing Examination (USMLE), Parts I, II, and III (Examination for Board-Certified Physicians in California)
- American Board of Ophthalmology (Board-Certified Ophthalmologist)
- Diplomate of the American Board of Ophthalmology
- Fellow of the American Academy of Ophthalmology
Post Graduate Training
- Chief Resident in Ophthalmology, Stanford University, Department of Ophthalmology 2004 – 05
- Ophthalmology Residency, Stanford University, Department of Ophthalmology 2002 – 05
- Medical Retina Research, Stanford University, Department of Ophthalmology, 2001 – 02 (pre-residency fellowship)
- Medical Internship, St. Mary’s Hospital, Internal Medicine 2000 – 01
- Post Doctoral Research, Stanford University Department of Neurobiology 1996 – 97
- Senior Research Scientist, Stanford University, Department of Ophthalmology, 2000 – 05
Private Practice Ophthalmology
- Medical Director, Founder of FishmanVision
- Harvey A. Fishman, MD, A Professional Corporation, Comprehensive Ophthalmology, 2007 -present
- Head of Cataract Service
- Academically Oriented Ophthalmology Practice in Santa Cruz, CA 2005 – 07
- Medical Staff, El Camino Hospital, Ophthalmology
- Co-Founder, EyeCareLive (CoolDoctors, Inc), 2016 – pres.
- Telemedicine solution for Ophthalmology and Optometry
- Co-Founder, AppMedicine, 2012 – 15
- Digital health platform (AppVisit) to enable providers to perform asynchronous virtual office visits.
- Co-Founder, MobileDx, 2010 – 12
- Developed Eyephotobill for billing external photos on the iphone and EyeSnapi, a prototype digital medical platform for ophthalmology e-visits. Iphone app innovations for ophthalmology.
- Co-Inventor of Sightmate (Low Vision Video Eyewear), Vuzix, 2007 – 08
- Video eyewear for patients with low vision focusing on Macular Degeneration (AMD) and Retinitis Pigmentosa (RP)
- Research Consultant, Caliper Technologies, 1996 – 97
- Research investigator for laboratory on a Chip: Micromachined Capillary Electrophoresis (CE) Chip Arrays to Screen for Novel Protease Inhibitors
Highlights from Dr. Fishman’s Curriculum Vitae
- Ophthalmology Training, Stanford Department of Ophthalmology
- Board-Certified American Board of Ophthalmology
- MD Stanford University School of Medicine
- PhD Stanford University Chemistry (Emphasis in laser chemistry)
- 40 Peer-reviewed Publications
- 11 U.S. Patents
- 27 Invited Talks including American Academy of Ophthalmology National Meeting Retina Subspeciality Day
- Founder and Former Director Stanford Ophthalmic Tissue Engineering Laboratory (thesis co-advisor to 4 graduate students in Applied Physics and Chemical Engineering)
- Founder of the Stanford Retinal Prosthesis Project in 2000
- Co-Authored 3 Major Research Grants, NIH, Stanford Bio-X
- Clinical Consultant to Major Ophthalmic Research Companies
- Ad hoc Reviewer, NIH Grants
- Manuscript Reviewer for Major Ophthalmology Journals including IOVS, Journal of Neural Engineering
- Dr. Fishman’s research discussed in Scientific American, The Economist, JAMA,
- Technology Review: An MIT Enterprise, Dr. Dean Edell, ABC 7 News San Francisco,
- The New Scientist, The Osgood Files on CBS Radio with Charles Osgood.
Dr. Fishman received his undergraduate B.S. degree in Chemistry with an emphasis in neuroscience. He then earned a Ph.D. from the Department of Chemistry at Stanford working with Professors Richard N. Zare and Richard H. Scheller in the area of lasers, microfluidics, and neuroscience. Dr. Fishman also conducted post-doctoral research in the Department of Neurobiology working in the field of nerve regeneration. He earned an M.D. from Stanford Medical School and completed a medical internship at St. Mary’s Hospital in San Francisco including training from San Francisco General Hospital. After his medical internship, Dr. Fishman joined Stanford Ophthalmology both as an ophthalmology resident and faculty and founded the Ophthalmic Tissue Engineering Laboratory (OTEL).
As director of OTEL, he was awarded one of the first Bio-X grants for his work on “The Artificial Synapse Chip” and founded the Stanford Artificial Retinal Prosthesis project where the IP was licensed by Pixium Vision (https://www.pixium-vision.com/prima-bionic-vision-system) and has recently entered into human clinical trials for patients with macular degeneration.
After completing his residency in eye surgery at Stanford, Dr. Fishman started FishmanVision, his own concierge ophthalmology practice in Palo Alto where he devotes his time between patient care, research, and entrepreneurial ventures. Dr. Fishman’s early venture was with Vuzix where he co-invented Sightmate, one of the first video eyewear devices for patients with macular degeneration and low vision. He then moved into the field of telemedicine where he co-founded 3 digital health start-ups including EyeCareLive, Inc, a video telemedicine solution for remote eye care.
His academic research has focused in the area of ocular surface disease diagnostics and treatment devices for dry eye, cancer detection, and the ocular microbiome. Dr. Fishman is conducting several on-going IRB clinical trials at FishmanVision in these areas. Most recently, he has worked in the field of artificial intelligence (AI) using deep based learning models and methods for enhancing clinical diagnosis in macular degeneration (OCT), low vision clinical assists (glaucoma bottle detection), and dry eye disease (meibography). Highlights of Dr. Fishman’s current research endeavors include the use of photobiomodulation for treatment of chalazions, digital health platforms for tele-ophthalmology/optometry, tear film liquid biopsy using Illumina RNA microarrays, and adapting AI algorithms to a smart phone platform for clinical diagnosis in ophthalmology.
Dr. Fishman has co-founded 4 silicon-valley start-ups, co-authored 41 Peer-reviewed Publications, 11 U.S. Patents, 3 pending patent applications, and his research has been highlighted in Scientific American, The Economist, JAMA, and recently in Ophthalmology Times.